Gd3+-DTPA-DG: novel nanosized dual anticancer and molecular imaging agent
What is it about?
Difficulties in the use, preparation, and cost of radioactively-labeled glycosylated compounds led to this research and development study of a new gadolinium-labeled glucose compound that does not have a radioactive half-life or difficulties in its synthesis and utilization.
Why is it important?
Application of GDD to cancer cells also increased levels of tumor necrosis factor alpha, but did not alter blood glucose levels. Interestingly, no toxicological findings were seen in normal human kidney cells.
The following have contributed to this page: Dr Saeed Shanehsazzadeh, Dr Masoud Ghorbani, and Dr bita Mehravi
In partnership with: